Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Effect of Short-term Oxygen During CPET in PH (ExOx-CPET)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2012 by University of Zurich.
Recruitment status was  Recruiting
Information provided by (Responsible Party):
University of Zurich Identifier:
First received: October 4, 2012
Last updated: December 12, 2012
Last verified: October 2012

In a randomized, sham-controlled trial the investigators will test whether supplemental oxygen given during cardiopulmonary exercise testing will improve exercise performance and physiological parameters in patients with pulmonary arterial or chronic thromboembolic pulmonary hypertension.

Condition Intervention Phase
Pulmonary Arterial and Chronic Thromboembolic Pulmonary Hypertension
Procedure: Supplemental oxygen via a mask
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Supportive Care
Official Title: Effect of Short-term Oxygen Therapy on Cardiopulmonary Exercise Capacity in Patients With Pulmonary Arterial and Chronic Thromboembolic Pulmonary Hypertension

Resource links provided by NLM:

Further study details as provided by University of Zurich:

Primary Outcome Measures:
  • Watt [ Time Frame: 1 day ] [ Designated as safety issue: No ]
  • exercise time [ Time Frame: 1 day ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Peak oxygen uptake [ Time Frame: 1 day ] [ Designated as safety issue: No ]
  • Respiratory exchange ratio [ Time Frame: 1 day ] [ Designated as safety issue: No ]
  • VE/VCO2 slope [ Time Frame: 1 day ] [ Designated as safety issue: No ]
  • PET CO2 [ Time Frame: 1 day ] [ Designated as safety issue: No ]
  • Changes in arterial blood parameters [ Time Frame: 1 day ] [ Designated as safety issue: No ]

Estimated Enrollment: 20
Study Start Date: December 2012
Estimated Study Completion Date: October 2014
Estimated Primary Completion Date: October 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Supplemental oxygen
Supplemental oxygen will be applied via a mask during CPET
Procedure: Supplemental oxygen via a mask
Placebo Comparator: Sham room air
Room air will be applied similarly to oxygen
Procedure: Supplemental oxygen via a mask


Ages Eligible for Study:   20 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion criteria:

  • diagnosis of pulmonary arterial hypertension class I and IV (according to the latest WHO classification scheme of Dana Point 2008)
  • on optimized medical therapy and in stable condition for at least 4 week
  • desaturate in the 6 minute walking test by at least 4% to values <92%

Exclusion criteria:

  • unstable conditions
  • pregnant women
  • patients with pulmonary venous hypertension
  • patients with relevant concomitant lung disease and severe daytime hypoxemia
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01748474

Contact: Silvia Ulrich Somaini, MD

University Hospital Zurich, Division of Pneumology Recruiting
Zurich, ZH, Switzerland, 8091
Sponsors and Collaborators
University of Zurich
Principal Investigator: Silvia Ulrich Somaini, MD University Hospital Zurich, Division of Pneumology
  More Information

No publications provided

Responsible Party: University of Zurich Identifier: NCT01748474     History of Changes
Other Study ID Numbers: KEK-ZH-NR. 2012-0251
Study First Received: October 4, 2012
Last Updated: December 12, 2012
Health Authority: Switzerland: Swissmedic

Additional relevant MeSH terms:
Hypertension, Pulmonary
Cardiovascular Diseases
Lung Diseases
Respiratory Tract Diseases
Vascular Diseases processed this record on November 27, 2014